ALENTIS THERAPEUTICS

Our team is committed to unlocking the broad potential of our therapeutic target Claudin-1 and bringing new treatments to those in need... We are a biotech company with a mission to treat cancer and reverse fibrosis. To this end, we are rapidly advancing our clinical pipeline of anti-Claudin-1 monoclonal antibodies... We have developed a promising pipeline of anti-Claudin-1 antibodies. Our two clinical candidates are in Phase 1/2 for solid tumors and Phase 2 for organ fibrosis, respectively. Beyond conventional therapies, our preclinical programs feature anti-Claudin-1 antibody-drug conjugates, bispecific antibodies, and T-cell engagers.

Also known as: Alentis Therapeutics AG

Primary location: Allschwil Switzerland